Atlas Venture Associates Opportunity I, L.P.'s Net Worth

$474 Million

Who is Atlas Venture Associates Opportunity I, L.P.?

Atlas Venture Associates Opportunity I, L.P. has an estimated net worth of $474 Million. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., and Third Harmonic Bio, Inc..

SEC CIK

Atlas Venture Associates Opportunity I, L.P.'s CIK is 0001780065

Past Insider Trading and Trends

2022 was Atlas Venture Associates Opportunity I, L.P.'s most active year for acquiring shares with 10 total transactions. Atlas Venture Associates Opportunity I, L.P.'s most active month to acquire stocks was the month of May. 2023 was Atlas Venture Associates Opportunity I, L.P.'s most active year for disposing of shares, totalling 31 transactions. Atlas Venture Associates Opportunity I, L.P.'s most active month to dispose stocks was the month of November. 2022 saw Atlas Venture Associates Opportunity I, L.P. paying a total of $34,090,021.70 for 16,180,239 shares, this is the most they've acquired in one year. In 2023 Atlas Venture Associates Opportunity I, L.P. cashed out on 675,637 shares for a total of $34,351,525.03, their largest year based on trade value.